RPG Investment Advisory LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 29.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 102,014 shares of the biopharmaceutical company’s stock after buying an additional 23,436 shares during the period. Gilead Sciences comprises 1.7% of RPG Investment Advisory LLC’s holdings, making the stock its 13th largest position. RPG Investment Advisory LLC’s holdings in Gilead Sciences were worth $7,876,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Reilly Financial Advisors LLC raised its holdings in Gilead Sciences by 98.3% in the 3rd quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 704 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Gilead Sciences in the 2nd quarter valued at about $132,000. Brand Asset Management Group Inc. bought a new position in Gilead Sciences in the 2nd quarter valued at about $139,000. TRUE Private Wealth Advisors bought a new position in Gilead Sciences in the 3rd quarter valued at about $174,000. Finally, Wealthsource Partners LLC bought a new position in Gilead Sciences in the 2nd quarter valued at about $206,000. Institutional investors own 78.09% of the company’s stock.
Shares of GILD opened at $71.18 on Friday. Gilead Sciences, Inc. has a 12 month low of $64.27 and a 12 month high of $89.54. The company has a market cap of $93.76 billion, a PE ratio of 8.32, a price-to-earnings-growth ratio of -2.81 and a beta of 1.01. The company has a current ratio of 3.45, a quick ratio of 3.39 and a debt-to-equity ratio of 1.09.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The company had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.44 billion. During the same period last year, the firm earned $2.27 earnings per share. As a group, equities analysts predict that Gilead Sciences, Inc. will post 6.44 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be issued a dividend of $0.57 per share. The ex-dividend date is Thursday, December 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.20%. Gilead Sciences’s dividend payout ratio is presently 26.64%.
Several research analysts have weighed in on the stock. Morgan Stanley increased their price target on shares of Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a report on Thursday, July 26th. Piper Jaffray Companies set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, September 12th. Mizuho set a $94.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, November 1st. Zacks Investment Research cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 25th. Finally, Raymond James lowered their price target on shares of Gilead Sciences from $97.00 to $94.00 and set a “strong-buy” rating on the stock in a report on Friday, October 26th. Twelve investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $87.84.
In other news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $69.55, for a total transaction of $3,477,500.00. Following the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at $213,362,847.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 150,000 shares of company stock worth $11,087,500 over the last ninety days. Insiders own 1.30% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Further Reading: Technical Analysis
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.